ACADIA Pharmaceuticals Inc.
ACAD
Classifica tra le azioni
#4463
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Prezzo delle azioni
$20.16
Capitalizzazione di mercato
$3.47B
Variazione (1 giorno)
-1.35%
Variazione (1 anno)
-5.20%
Paese
US
Scambia ACADIA Pharmaceuticals Inc. (ACAD)
Categoria
Healthcare
Storico del prezzo dell'azione per ACADIA Pharmaceuticals Inc. (ACAD)
Prezzo di chiusura più alto: $19.68 il 2026-10-01
Prezzo di chiusura più basso: $6.66 il 2004-05-01
Prezzo di chiusura più basso: $6.66 il 2004-05-01
Storico del prezzo dell'azione di ACADIA Pharmaceuticals Inc. dal 2004 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -10.49% |
| 2025 | 55.58% |
| 2024 | -35.30% |
| 2023 | 74.02% |
| 2022 | -32.82% |
| 2021 | -57.69% |
| 2020 | 18.76% |
| 2019 | 165.62% |
| 2018 | -42.16% |
| 2017 | 8.65% |
| 2016 | -22.24% |
| 2015 | 11.41% |
| 2014 | 29.97% |
| 2013 | 416.58% |
| 2012 | 328.70% |
| 2011 | 23.06% |
| 2010 | -30.48% |
| 2009 | 14.05% |
| 2008 | -90.54% |
| 2007 | 30.89% |
| 2006 | -8.44% |
| 2005 | 48.01% |
| 2004 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.25 | -3.37% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
